CTRI/2011/11/002098暂停3 期
A Prospective, open-label, non-controlled, multicenter, phase III clinical study to evaluate the efficacy and safety of immunoglobulin intravenous (human) 10% (NewGam) inPrimary Immune Thrombocytopenia - NI
试验速览
- 阶段
- 3 期
- 状态
- 暂停
- 入组人数
- 95
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age of >=18 years and <=65 years.
- •2. Confirmed diagnosis of chronic primary ITP (threshold platelet count less than 100x109/L) of at least 12 months duration and fulfilling the following criteria:
- •a) history and physical examination excluding other causes of thrombocytopenia b) pattern of bleeding associated with platelet disorders using the verbal rating scale according to Buchanan (2002) [8].
- •c) isolated thrombocytopenia in the blood count; apart from thrombocytopenia, the blood count is normal for the patientâ??s age, or if abnormal, readily explained
- •d) peripheral blood smear consistent with ITP: thrombocytopenia with platelets of normal size or slightly larger than normal, with absence of platelet clumps and giant platelets; normal red and white blood cell morphology
- •e) when any abnormal finding is present, additional diagnostic evaluation exclude other causes of thrombocytopenia.
- •3. Platelet count of <=20x109/L with or without bleeding manifestations.
- •4.Freely given written informed consent from patient.
- •5.Women of childbearing potential must have a negative result on a pregnancy test (human chorionic gonadotropine [HCG]-based assay) and need to practice contraception using a method of proven reliability for the duration of the study.
- •Note:In India as per the DCGI cap we will include patients from the age of 18 to 65 yrsâ??
排除标准
- •1.Thrombocytopenia secondary to other diseases (such as Acquired Immunodeficiency Syndrome [AIDS] or systemic lupus erythematosus [SLE]) or drug-related thrombocytopenia.
- •2.Administration of intravenous immunoglobulin (IGIV), anti-D or thrombopoetin receptor agonists or other platelet enhancing drugs (incl. immunosuppressive or other immunomodulatory drugs) within 3 weeks before enrollment, except for:
- •a) long-term corticosteroid therapy when the dose has been stable during the preceding 3 weeks and no dosage change is planned until study Day 22.
- •b) long-term azathioprine, cyclophosphamide or attenuated androgen therapy when the dose has been stable during the preceding 3 months and no dosage change is planned until study Day 22.
- •3.Unresponsive to previous treatment with IGIV or anti-D immunoglobulin.
- •4.Experimental treatment (e.g. Rituximab) within 3 months before enrollment.
- •5.Splenectomy in the previous 4 weeks or planned splenectomy throughout the study period.
- •6.Subject with Evans syndrome (autoimmune thrombocytopenia and autoimmune hemolysis).
- •7.Known or suspected human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection
- •8.Live viral vaccination within the last two months before study entry.
- •9.Emergency operation.
- •10. Severe liver or kidney disease (alanine aminotransferase [ALAT] 3x > upper limit of normal, creatinine >120 µmol/L).
- •11. Congestive heart failure New York Heart Association (NYHA) class III or IV.
- •12. Non-controlled arterial hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >90 mmHg).
- •13. History of hypersensitivity to blood or plasma derived products, or any component of the investigational product.
- •14. Known immunoglobulin A (IgA) deficiency and antibodies against IgA.
- •15. History of, or suspected alcohol or drug abuse.
- •16. Pregnant or nursing women.
- •17. Unable or unwilling to comply with the study protocol.
- •18. Participating in another interventional clinical study and receiving investigational medicinal product within three months before study entry.
- •19. Patients with body mass index >= 30kg /m2
- •20. Patients with risk factors(i) for thromboembolic events in whom the risks outweigh the potential benefit of NewGam treatment
- •(i) Such as obesity,advanced age , hypertension, diabetes, a history of atheroschlerosis/vascular disease or thrombotic events , hyperlipidaemia, multiple cardiovascular risk factors, acquired or inherited thrombophilic disorders, prolonged periods of immobilization, severe hypvoleamia, central venous catheterization, active malignancy and/or known or suspected hyperviscosity.
研究者
相似试验
已完成
不适用
A safety study of Neucrylate AN™ Liquid Embolic System for the treatment of cerebral berry aneurysmsISRCTN36582296Valor Medical Inc. (USA)40
进行中（未招募）
1 期
A study to evaluate clear skin effect in patients with plaque psoriasis.Plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858EUCTR2015-003701-42-LTovartis Pharma Services AG1,615
进行中（未招募）
1 期
A study to evaluate clear skin effect in patients with plaque psoriasis.Plaque psoriasisEUCTR2015-003701-42-ESovartis Farmacéutica, S.A.1,615
进行中（未招募）
1 期
A study to evaluate clear skin effect in patients with plaque psoriasis.MedDRA version: 18.1 Level: LLT Classification code 10050576 Term: Psoriasis vulgaris System Organ Class: 100000004858Plaque psoriasisEUCTR2015-003701-42-PTovartis Pharma Services AG1,660
进行中（未招募）
1 期
A study to evaluate clear skin effect in patients with plaque psoriasis.MedDRA version: 18.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858Plaque psoriasisEUCTR2015-003701-42-BEovartis Pharma Services AG1,615